financetom
Business
financetom
/
Business
/
Dorsey-led Square rebrands to Block in nod to blockchain
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Dorsey-led Square rebrands to Block in nod to blockchain
Dec 2, 2021 12:45 AM

Square Inc, the payments company led by Twitter Inc co-founder Jack Dorsey, said on Wednesday it was changing its name to Block Inc, as it looks to expand beyond its payment business and into new technologies like blockchain.

Share Market Live

NSE

The San Francisco-based company said the name "Square" had become synonymous with it's seller business. The new name would distinguish the corporate entity from its businesses, Square added, a strategy similar to Meta Platforms Inc's rebrand last month.

The company said there would be no organizational changes and its different business units - Square, peer-to-peer payment service Cash App, music streaming service Tidal and its bitcoin-focused financial services segment TBD54566975 - will continue to maintain their respective brands. Shares were up nearly 1% in extended trading.

"The name has many associated meanings for the company — building blocks, neighborhood blocks and their local businesses, communities coming together at block parties full of music, a blockchain, a section of code, and obstacles to overcome," Square said in a statement.

The move comes days after Dorsey stepped down from his role as chief executive officer at Twitter. The digital payments giant's Square Crypto, a team "dedicated to advancing Bitcoin", will also change its name to Spiral.

Under Dorsey, who has frequently expressed his interest in the cryptocurrency, Square bought $50 million worth of bitcoin even before the wave of institutional interest that propelled the digital currency's price to record highs this year. In February, it further raised its wager and invested another $170 million in it.

Square has also been weighing the creation of a hardware wallet for bitcoin to make its custody more mainstream.

The new name would become effective on or about Dec. 10, Square said, but the "SQ" ticker symbol on the New York Stock Exchange would not change at this time.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Candel Therapeutics Shares Rise After FDA Orphan Drug Designation for Potential Pancreatic Cancer Drug
Candel Therapeutics Shares Rise After FDA Orphan Drug Designation for Potential Pancreatic Cancer Drug
Apr 11, 2024
09:46 AM EDT, 04/11/2024 (MT Newswires) -- Candel Therapeutics ( CADL ) shares jumped 27.5% in recent trading Thursday after the company said its potential treatment for pancreatic cancer CAN-2409 has received orphan drug designation from the US Food and Drug Administration. Recently reported data from a phase 2 clinical trial showed that when added to standard of care, CAN-2409...
Payoneer Global Insider Sold Shares Worth $2,697,206, According to a Recent SEC Filing
Payoneer Global Insider Sold Shares Worth $2,697,206, According to a Recent SEC Filing
Apr 11, 2024
09:56 AM EDT, 04/11/2024 (MT Newswires) -- Scott H. Galit, Director, around April 08, 2024, sold 554,662 shares in Payoneer Global ( PAYO ) for $2,697,206. Following the Form 4 filing with the SEC, Galit has control over a total of 2,667,422 shares of the company, with 2,667,422 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1845815/000095010324005136/xslF345X03/dp209676_4-galit.xml Price: 4.86, Change: -0.01, Percent Change:...
Teva Pharmaceutical Unit Says Late-Stage Trial in China of Ajovy to Prevent Migraine Achieves Primary, Secondary Endpoints
Teva Pharmaceutical Unit Says Late-Stage Trial in China of Ajovy to Prevent Migraine Achieves Primary, Secondary Endpoints
Apr 11, 2024
09:46 AM EDT, 04/11/2024 (MT Newswires) -- Teva Pharmaceutical Industries ( TEVA ) unit Teva Pharmaceuticals said Thursday that a late-stage trial in China assessing the efficacy and safety of Ajovy to prevent migraine in adults achieved the primary endpoint and all secondary endpoints. The company said the drug significantly decreased the number of migraine days seen per month and...
Docusign Insider Sold Shares Worth $900,000, According to a Recent SEC Filing
Docusign Insider Sold Shares Worth $900,000, According to a Recent SEC Filing
Apr 11, 2024
09:50 AM EDT, 04/11/2024 (MT Newswires) -- Peter Solvik, Director, on April 09, 2024, sold 15,000 shares in Docusign ( DOCU ) for $900,000. Following the Form 4 filing with the SEC, Solvik has control over a total of 233,055 shares of the company, with 783 shares held directly and 232,272 shares controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1261333/000126133324000050/xslF345X03/wk-form4_1712793182.xml Price: 59.30, Change:...
Copyright 2023-2026 - www.financetom.com All Rights Reserved